May 26th, 2020 | Pessac, FRANCE
“The formation of Poietis’ SAB is a very important step towards company global deployment in the clinical area” says Bruno Brisson, Poietis co-founder and VP Business Development. “We are delighted to welcome Dr. Gurtner and Dr. May to our SAB, where they will be key contributors in further enhancing our efforts to bring bioprinting solutions to clinicians and patients with high unmet needs”.
“To have Dr. Gurtner, a world-renowned expert in tissue-engineering therapies for skin wound healing, join our SAB will enrich our R&D efforts to achieve the first-in-human of a bioprinted skin substitute in the coming years” adds Dr. Fabien Guillemot, CEO and Poietis founder. “We also believe Dr. May will prove invaluable to Poietis leadership team, and we look forward to his insights and guidance to accelerate the advancement of our bioprinting platform technology to address the key challenges in tissue manufacturing and regenerative medicine”.
“3D bioprinting is a once-in-a-generation transformative technology. By focusing its 3D printing platform on a clinical application of high unmet need, Poietis is leading the adoption of 3D printing in cell therapy and tissue engineering” comments Dr. Michael H. May, PhD, President & CEO of the CCRM.
Dr. Geoffrey Gurtner, MD, is Johnson and Johnson Professor of Surgery and Professor of Materials Science and Engineering at Stanford University, California; USA. He currently serves as the Associate Chairman for Research in the Department of Surgery and is the Executive Director of the
Stanford Wound Care Center.
Geoff is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California-San Francisco School of Medicine.
He completed a general surgery residency at Massachusetts General Hospital, a plastic surgery residency at NYU School of Medicine and received advanced training in microsurgery at the University of Texas-MD Anderson Cancer Center. He is board certified in both general surgery and plastic surgery. He is the author of over 180 peer-reviewed publications in both scientific and surgical literature and editor for two major textbooks in the field: Grabb & Smith’s Plastic Surgery and Plastic Surgery. Geoff was awarded the James Barrett Brown Award (for best paper in plastic surgery) in both 2009 and 2010, and has been named “Researcher of the Year” by the American Society of Plastic Surgeons and the American Association of Plastic Surgeons. His research has led to the development of several novel biomedical technologies. Geoff has co-founded several start-ups focused on wound healing, aesthetics and cardiovascular health.
Dr. Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin
Walmsley Fellowship for Technological Entrepreneurship. He is President and Chief Executive Officer of the Center for Commercialization of Regenerative Medicine (CCRM) – a Canadian public-private partnership supporting the translation and commercialization of cell & gene therapies and associated enabling technologies through stakeholder networks and with specialized teams, infrastructure and funding. He is also CEO of CCRM Enterprises, the venture creation and investment arm of CCRM.
Prior to CCRM, Michael was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. Rimon’s initial focus was on advanced wound healing. Michael sits on a number of boards and advisory committees, including: the Entrepreneurship Leadership Council at the University of Toronto; the Commercialization Committee of the International Society for Cell and Gene Therapy, the Alliance for Regenerative Medicine Foundation, CellCan and AgeX Inc. He is Chair of ExcellThera and co-moderates sessions in the health streams of the Creative Destruction Labs.
About Poietis :
Press contact :